Polymorphisms of paraoxonase 1 and 2 genes and the risk of multiple sclerosis in the polish population;Polimorfizmy genów paraoksonazy 1 oraz 2 jako czynnik ryzyka rozwoju stwardnienia rozsianego w populacji polskiej

Neurologia i Neurochirurgia Polska

Volumn 47, Issue 1, 2013, Pages 49-52

  Zakrzewska Pniewska, Beata ^a   Nojszewska, Monika ^a   Róg, Teresa ^b   Pniewski, Jarosław ^c   Dorobek, Małgorzata ^c   Styczyńska, Maria ^d   Szczudlik, Andrzej ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c Klinika Neurologii   (Poland)

^d MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Multiple sclerosis; Polymorphism; PON1; PON2

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DNA POLYMORPHISM; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PARAOXONASE 1 GENE; PARAOXONASE 2 GENE; POLYMERASE CHAIN REACTION; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84875068503     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.5114/ninp.2013.32935     Document Type: Article

References (14)

1. Compston A., Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
2. van Horssen J., Witte M.E., Schreibelt G., et al. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta 2011; 1812: 141-150.
3. Li H.L., Liu D.P, Liang C.C. Paroxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 2003; 81: 766-779.
4. Percourt L.-P, Amre D., Denis M.-C., et al. The three-gene paroxonase family: physiologic roles, actions and regulation. Atherosclerosis 2011; 214: 20-36.
5. McDonald W.I., Compston A., Eddan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2005; 50: 121-127.
6. Ombres D., Pannitteri G., Montali A., et al. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Btol 1998; 18: 1611-1616.
7. Mackness B., Durrington PN., Abuashia B., et al. Low paraox-onase activity in type II diabetes mellitus complicated by retinopathy Cltn Sci (Lond) 2000; 98: 355-363.
8. Zawiślak D., Ostrowska M., Golenia A., et al. The -A162G polymorphism of the PON1 gene and the risk of sporadic amyotrophic lateral sclerosis. Neurol Neurochir Pol 2010; 44: 246-250.
9. Newcombe J., Li H., Cuzner M.L. Low density lipoprotein uptake by microphages in multiple sclerosis plaques: implications for pathogenesis. Neuropathol Appl Neurobiol 1994; 20: 152-162.
10. Besler H.T, Comoglu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 2003; 6: 189-196.
11. Ferretti G., Bacchetti T, Principi F., et al. Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paroxonase activity. Mult Scler 2005; 11: 677-682.
12. Ferretti G., Bacchetti T, DiLudovico F, et al. Intracellular oxidative activity and respiratory burst of leukocytes isolated from multiple sclerosis patients. Neurochem Int 2006; 48: 87-92.
13. Sidoti A., Antognelli C., Rinaldi C., et al. Glyoxalase IA111E, paroxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis? Mult Scler 2007; 13: 446-453.
14. Martinez C., Garcia-Martin E., Benito-Leon J., et al. Paraoxo-nase 1 polymorphysms are no related with the risk for multiple sclerosis. Neuromol Med 2010; 12: 217-223.